Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes

David A. Rodeberg, Rebecca A. Nuss, Sherine F. Elsawa, Courtney L. Erskine, Esteban Celis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The transcription factor PAX3 is expressed during early embryogenesis and in multiple cancer types, including embryonal rhabdomyosarcoma (ERMS), Ewing sarcoma (ES) and malignant melanoma (MEL), suggesting that it could function as a general tumor associated antigen. Major histocompatibility complex (MHC) peptide binding algorithms were used to predict potential epitopes in PAX3 capable of stimulating in vitro naïve HLA-A0201 restricted cytotoxic T-lymphocytes (CTLs). Two peptides, PAX3-282 (QLMAFNHLI) and a modified version of this peptide PAX3-282.9V (QLMAFNHLV), were capable of inducing antigen-specific CTLs. Of these peptides, PAX3-282.9V was the most efficient inducer of primary CTL response. These CTLs were able to lyse HLA-A0201 expressing target cells that were pulsed with peptide, and more importantly, were effective in killing tumor cells that express PAX3, including ERMS, ES and MEL cell lines. These findings provide compelling evidence that peptide PAX3-282 is naturally processed by tumors and is presented in the context of HLA-A0201 in adequate amounts to allow CTL recognition. Also, PAX3-282.9V is an effective immunogenic peptide able to induce CTL recognition of PAX3-containing tumors and may be used as an antitumor peptide vaccine.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalInternational Journal of Cancer
Volume119
Issue number1
DOIs
StatePublished - Jul 1 2006

Fingerprint

Cytotoxic T-Lymphocytes
Antigens
Peptides
Embryonal Rhabdomyosarcoma
Ewing's Sarcoma
Melanoma
Neoplasms
Subunit Vaccines
Neoplasm Antigens
Major Histocompatibility Complex
Embryonic Development
Epitopes
Cell Line
HLA-A*02:01 antigen

Keywords

  • Cancer vaccine
  • Immunotherapy
  • Melanoma
  • Sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. / Rodeberg, David A.; Nuss, Rebecca A.; Elsawa, Sherine F.; Erskine, Courtney L.; Celis, Esteban.

In: International Journal of Cancer, Vol. 119, No. 1, 01.07.2006, p. 126-132.

Research output: Contribution to journalArticle

Rodeberg, David A. ; Nuss, Rebecca A. ; Elsawa, Sherine F. ; Erskine, Courtney L. ; Celis, Esteban. / Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. In: International Journal of Cancer. 2006 ; Vol. 119, No. 1. pp. 126-132.
@article{dc2b40a07b5846898e3dc9acbb0ebcd8,
title = "Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes",
abstract = "The transcription factor PAX3 is expressed during early embryogenesis and in multiple cancer types, including embryonal rhabdomyosarcoma (ERMS), Ewing sarcoma (ES) and malignant melanoma (MEL), suggesting that it could function as a general tumor associated antigen. Major histocompatibility complex (MHC) peptide binding algorithms were used to predict potential epitopes in PAX3 capable of stimulating in vitro na{\"i}ve HLA-A0201 restricted cytotoxic T-lymphocytes (CTLs). Two peptides, PAX3-282 (QLMAFNHLI) and a modified version of this peptide PAX3-282.9V (QLMAFNHLV), were capable of inducing antigen-specific CTLs. Of these peptides, PAX3-282.9V was the most efficient inducer of primary CTL response. These CTLs were able to lyse HLA-A0201 expressing target cells that were pulsed with peptide, and more importantly, were effective in killing tumor cells that express PAX3, including ERMS, ES and MEL cell lines. These findings provide compelling evidence that peptide PAX3-282 is naturally processed by tumors and is presented in the context of HLA-A0201 in adequate amounts to allow CTL recognition. Also, PAX3-282.9V is an effective immunogenic peptide able to induce CTL recognition of PAX3-containing tumors and may be used as an antitumor peptide vaccine.",
keywords = "Cancer vaccine, Immunotherapy, Melanoma, Sarcoma",
author = "Rodeberg, {David A.} and Nuss, {Rebecca A.} and Elsawa, {Sherine F.} and Erskine, {Courtney L.} and Esteban Celis",
year = "2006",
month = "7",
day = "1",
doi = "10.1002/ijc.21817",
language = "English (US)",
volume = "119",
pages = "126--132",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes

AU - Rodeberg, David A.

AU - Nuss, Rebecca A.

AU - Elsawa, Sherine F.

AU - Erskine, Courtney L.

AU - Celis, Esteban

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The transcription factor PAX3 is expressed during early embryogenesis and in multiple cancer types, including embryonal rhabdomyosarcoma (ERMS), Ewing sarcoma (ES) and malignant melanoma (MEL), suggesting that it could function as a general tumor associated antigen. Major histocompatibility complex (MHC) peptide binding algorithms were used to predict potential epitopes in PAX3 capable of stimulating in vitro naïve HLA-A0201 restricted cytotoxic T-lymphocytes (CTLs). Two peptides, PAX3-282 (QLMAFNHLI) and a modified version of this peptide PAX3-282.9V (QLMAFNHLV), were capable of inducing antigen-specific CTLs. Of these peptides, PAX3-282.9V was the most efficient inducer of primary CTL response. These CTLs were able to lyse HLA-A0201 expressing target cells that were pulsed with peptide, and more importantly, were effective in killing tumor cells that express PAX3, including ERMS, ES and MEL cell lines. These findings provide compelling evidence that peptide PAX3-282 is naturally processed by tumors and is presented in the context of HLA-A0201 in adequate amounts to allow CTL recognition. Also, PAX3-282.9V is an effective immunogenic peptide able to induce CTL recognition of PAX3-containing tumors and may be used as an antitumor peptide vaccine.

AB - The transcription factor PAX3 is expressed during early embryogenesis and in multiple cancer types, including embryonal rhabdomyosarcoma (ERMS), Ewing sarcoma (ES) and malignant melanoma (MEL), suggesting that it could function as a general tumor associated antigen. Major histocompatibility complex (MHC) peptide binding algorithms were used to predict potential epitopes in PAX3 capable of stimulating in vitro naïve HLA-A0201 restricted cytotoxic T-lymphocytes (CTLs). Two peptides, PAX3-282 (QLMAFNHLI) and a modified version of this peptide PAX3-282.9V (QLMAFNHLV), were capable of inducing antigen-specific CTLs. Of these peptides, PAX3-282.9V was the most efficient inducer of primary CTL response. These CTLs were able to lyse HLA-A0201 expressing target cells that were pulsed with peptide, and more importantly, were effective in killing tumor cells that express PAX3, including ERMS, ES and MEL cell lines. These findings provide compelling evidence that peptide PAX3-282 is naturally processed by tumors and is presented in the context of HLA-A0201 in adequate amounts to allow CTL recognition. Also, PAX3-282.9V is an effective immunogenic peptide able to induce CTL recognition of PAX3-containing tumors and may be used as an antitumor peptide vaccine.

KW - Cancer vaccine

KW - Immunotherapy

KW - Melanoma

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=33646522424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646522424&partnerID=8YFLogxK

U2 - 10.1002/ijc.21817

DO - 10.1002/ijc.21817

M3 - Article

C2 - 16450380

AN - SCOPUS:33646522424

VL - 119

SP - 126

EP - 132

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -